Clinical Benefit From BRAF/MEK Inhibition in a Double Non-V600E BRAF Mutant Lung Adenocarcinoma: A Case Report

Clin Lung Cancer. 2019 May;20(3):e219-e223. doi: 10.1016/j.cllc.2019.02.022. Epub 2019 Mar 4.
No abstract available

Keywords: BRAF kinase activity; BRAF mutation; BRAF/MEK blockade; NGS; NSCLC.

Publication types

  • Case Reports

MeSH terms

  • Adenocarcinoma of Lung / drug therapy*
  • Adenocarcinoma of Lung / genetics
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • High-Throughput Nucleotide Sequencing
  • Humans
  • Imidazoles / therapeutic use*
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / genetics
  • Male
  • Mutation / genetics
  • Neoplasm Metastasis
  • Oximes / therapeutic use*
  • Protein Kinase Inhibitors / therapeutic use*
  • Proto-Oncogene Proteins B-raf / antagonists & inhibitors
  • Proto-Oncogene Proteins B-raf / genetics*
  • Pyridones / therapeutic use*
  • Pyrimidinones / therapeutic use*
  • Remission Induction
  • Treatment Outcome

Substances

  • Imidazoles
  • Oximes
  • Protein Kinase Inhibitors
  • Pyridones
  • Pyrimidinones
  • trametinib
  • BRAF protein, human
  • Proto-Oncogene Proteins B-raf
  • dabrafenib